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AbsTrACT
Objective higher gluten intake, frequent 
gastrointestinal infections and adenovirus, enterovirus, 
rotavirus and reovirus have been proposed as 
environmental triggers for coeliac disease. however, it 
is not known whether an interaction exists between 
the ingested gluten amount and viral exposures in the 
development of coeliac disease. This study investigated 
whether distinct viral exposures alone or together with 
gluten increase the risk of coeliac disease autoimmunity 
(cDa) in genetically predisposed children.
Design The environmental Determinants of Diabetes 
in the Young study prospectively followed children 
carrying the hla risk haplotypes DQ2 and/or DQ8 and 
constructed a nested case–control design. From this 
design, 83 cDa case–control pairs were identified. 
Median age of cDa was 31 months. stool samples 
collected monthly up to the age of 2 years were analysed 
for virome composition by illumina next- generation 
sequencing followed by comprehensive computational 
virus profiling.
results The cumulative number of stool enteroviral 
exposures between 1 and 2 years of age was associated 
with an increased risk for cDa. in addition, there was 
a significant interaction between cumulative stool 
enteroviral exposures and gluten consumption. The risk 
conferred by stool enteroviruses was increased in cases 
reporting higher gluten intake.
Conclusions Frequent exposure to enterovirus between 
1 and 2 years of age was associated with increased risk 
of cDa. The increased risk conferred by the interaction 
between enteroviruses and higher gluten intake indicate 
a cumulative effect of these factors in the development of 
cDa.
InTrODuCTIOn
The incidence of autoimmune diseases is rising more 
rapidly than can be explained by genetics, supporting 
the role of environmental factors in the disease patho-
genesis.1 Coeliac disease, a dietary gluten- driven 
chronic small bowel enteropathy, is characterised by 
an autoimmune response against tissue transglutami-
nase (tTG). The main autoantigen in coeliac disease 
is tTG, which post- translationally deamidates gluten- 
derived gliadin peptides.2 Coeliac disease autoim-
munity (CDA), which refers to the appearance of 
significance of this study
What is already known on this subject?
 ► Intake of high amounts of gluten increases 
the risk of coeliac disease in genetically 
predisposed children.
 ► Gastrointestinal infections have been 
associated with an increased risk of coeliac 
disease.
What are the new findings?
 ► The prospective metagenomics screening of the 
stool virome shows that the cumulative number 
of stool enteroviral exposures between 1 and 2 
years of age are associated with an increased 
risk for coeliac disease autoimmunity.
 ► There is an interaction between cumulative 
enteroviral exposures between 1 and 2 years of 
age with cumulative gluten intake by 2 years 
of age in relation to the risk of coeliac disease 
autoimmunity.
 ► The effect of enteroviruses on the risk of coeliac 
disease autoimmunity is higher when greater 
amounts of gluten are consumed.
How might it impact on clinical practice in the 
foreseeable future?
 ► This study suggests that enteroviral infections 
early in life are potentiated by high gluten 
intake, which may trigger the development of 
coeliac disease autoimmunity in genetically 
predisposed children.
 ► More studies are needed to evaluate potential 
pathogenetic mechanisms of this interaction, 
which could offer new opportunities for the 
development of preventive strategies for 
coeliac disease.
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Figure 1 Flow chart describing the selection of the CDA case–control 
pairs for the study. CDA, coeliac disease autoimmunity; IA; islet 
autoantibody; NCC, nested case–control; T1D, type 1 diabetes.
Table 1 Demographic data of the 83 nested case and control pairs
Cases Controls
HLA genotype, n (%)
  DQ2/DQ2 29 (35) 11 (13)
  DQ2/DQ8 39 (47) 36 (43)
  DQ8/DQ8 11 (13) 20 (24)
  DQ8/X 4 (5) 15 (19)
  Other (ineligible) 1 (1)
Age at CDA, months 31 (23, 46) NA
Developed CD during follow- up, n (%) 28 (34) NA
With CD- FDR, n (%) 6 (7) 3 (4)
Breastfeeding
  Ever breastfed, n (%) 83 (100) 83 (100)
  Breastfeeding stopped, months 8 (5, 11) 8 (4, 12)
Gluten
  Age at introduction, months 6 (5, 7) 6 (5, 7)
  Total intake by 2 years of age (g) 8.0 (5.4, 11.0) 7.6 (5.0, 11.8)
IA positivity, n (%) 41 (49) 15 (18)
  Prior to CDA, n (%) 31 (37) NA
For continuous variables, the median (25th percentile, 75th percentile) is reported.
CD, coeliac disease; CDA, coeliac disease autoimmunity; CD- FDR, subject having a 
first degree relative with coeliac disease; IA, islet autoantibody; NA, not applicable.
serum tTG autoantibodies, is indicative of ongoing gluten- induced 
inflammatory response and may precede small bowel mucosal 
damage.3 4
Higher gluten intake increases the risk of coeliac disease.5 6 
However, it is not clear why not all genetically predisposed HLA- 
DQ2 and/or DQ8 positive individuals who eat gluten develop 
the disease. As a result, reasons leading to breakage of oral toler-
ance for gluten in coeliac disease remain unresolved. The possible 
role of infections in the development of coeliac disease has been 
supported in previous observational studies.7–10 These investiga-
tions have been extended by other studies, pointing to a potential 
role of viral infections, particularly by adenovirus, enterovirus, 
rotavirus and reovirus, in the disease pathogenesis.10–15However, 
these findings are mainly based on cross- sectional or experimental 
studies. Thus, prospective studies are warranted to clarify if a 
virus or a group of viruses are involved in the aetiology of coeliac 
disease. More importantly, studies are limited in investigating a 
possible interaction between viral infections and gluten intake.
This study investigated the viral exposures prior to develop-
ment of CDA from serial stool samples collected from children 
followed in a prospective birth cohort at genetic risk for both 
type 1 diabetes (T1D) and coeliac disease. By examining next- 
generation sequencing (NGS) metagenomics data, we assessed 
if viruses detected in the stool are associated with CDA and 
whether this association involved a possible interaction with 
gluten intake.
MATerIAls AnD MeTHODs
 The nested case–control (nCC) study design
Following new- born screening for high- risk HLA- DR- DQ geno-
types, The Environmental Determinants of Diabetes in the Young 
(TEDDY) enrolled 8676 children before 4.5 months of age for a 
15- year follow- up study with the main aim of identifying genetic 
and environmental triggers associated with T1D and coeliac 
disease.16 Annual screening for CDA started at the age of 2 years 
by detection of tTG autoantibodies using radiobinding assays, as 
previously described.17 If a sample was tTG- autoantibody posi-
tive, all of the child’s earlier available samples were tested to 
determine the age of seroconversion. CDA was defined as being 
positive for tTG autoantibodies in two consecutive samples at 
least 3 months apart.18
From this cohort, two nested case–control (NCC) studies were 
constructed to improve the efficiency of multiple biomarker 
studies, with one focused on islet autoimmunity (IA) and the 
other on T1D. Cases and controls were identified as of 31 May 
2012, then all available samples meeting the design criteria by 
that time were processed in the laboratories chosen for each 
biomarker analysis. Case–control pairs were matched for T1D 
family history (defined as having a first- degree relative with 
T1D), gender and clinical site location in the region where the 
participant was enrolled.19 All children in the 1:1 NCC studies 
for gut virome analysis that had been screened for CDA were 
considered for the present study. Each case–control pair included 
a CDA positive child (‘case’) matched with a child (‘control’) 
who was CDA- free for at least 6 months from the CDA case’s 
age of seroconversion.
Identified were 88 CDA case–control pairs. Among those, only 
the 83 pairs (44 were females and 39 were males) whose stool 
virome data were available after introducing gluten in their diet 
were included in the final analysis (figure 1, table 1). The distri-
bution by country was as follows: USA (n=25), Finland (n=13), 
Germany (n=5) and Sweden (n=40). There were 16 pairs with 
family history of T1D. Of the CDA cases, 41 were confirmed for 
IA positivity and 31 of these developed IA prior to CDA. Of the 
controls, 11 were IA positive. During the follow- up, 28 of the 
CDA cases developed coeliac disease. Six CDA cases and three 
controls had a first- degree relative with coeliac disease. As for 
the rotavirus vaccination status, 15 CDA cases and 20 controls 
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Figure 2 Stool samples positive for (A) any of the investigated viruses and (B) enteroviruses by 2 years of age as a percentage of samples available 
at each collection age. Filled triangles denote cases with CDA and unfilled circles controls. Bars represent the percentage of case–control pairs from 
whom stool samples were available for analysis at each collection age. CDA, coeliac disease autoimmunity.
were vaccinated. Other characteristics of the cases and controls 
are shown in table 1.
 Detection of viral stool sequences
Stool samples were collected monthly from 3 months until 2 
years of age. NGS viral sequences were assayed in serial stool 
samples using a custom offline version of Vipie.20 Vipie virus 
population profiling pipeline components include standard 
scripts for base quality, trimming, chimaera detection while de 
novo assembled contigs were generated via integration of local 
assembly methods SPAdes and Velvet.21 22 These contigs were 
mapped to NCBI virus database using BLAST23 resulting in a 
sample- based general virus population profile. For the present 
study, we focused on enterovirus, adenovirus, astrovirus, noro-
virus, reovirus and rotavirus. To approximate serotype and 
increase specificity, viral structural capsid- specific remapping 
on positive NGS samples was performed for enteroviruses 
and adenoviruses. For this analysis, MAPQ alignment cut- off 
of 20, representing greater than 0.99 probability was applied. 
The capsid resource contains Genbank and Tampere Virology 
Group- selected strains of adenovirus hexon, fibre and penton 
regions as well as enterovirus strains Coxsackievirus A, Coxsack-
ievirus B and selected Echovirus P1 protein (VP1-4) regions. This 
study included 1507 samples processed, after introducing gluten 
in diet.
 Dietary data from food records
By 2 years of age, information on breastfeeding and the timing 
of introduction to gluten- containing cereals were collected from 
validated questionnaires at each clinic visit occurring every 
3 months.5 Information on gluten consumption was collected at 
each clinic visit every 3 months up to 1 year of age and biannu-
ally thereafter (24 hours recall at 3- month visit and subsequently 
3- day food records). Amount of gluten intake was calculated by 
multiplying the amount of vegetable protein in gluten- containing 
flours by a factor of 0.8.24 From the 3- day food records, daily 
consumption (g/day) was obtained as the mean of 3 days of 
consumption.
 statistical analysis
The case–control pairs identified from the TEDDY NCC design 
were used to examine whether viral profiles differed by the CDA 
status. Conditional logistic regression was used to compare the 
cumulative appearance of viral exposures, after adjusting for 
HLA. Viral exposures were categorised by age:<1 year of life and 
from 1 to <2 years of life. From pairs where the case serocon-
verted prior to 2 years of age, only the samples available prior to 
age of seroconversion were included in the analysis. Interaction 
with cumulative gluten intake on the risk of CDA was examined. 
The cumulative gluten intake was obtained from the sum of daily 
consumption (g/day) from all clinical visits by 2 years of age. 
None reported any gluten consumption at 3- month visit. Addi-
tionally, the effects of the enterovirus sequence reads from 1 to 
<2 years of life were assessed in three groups by the total gluten 
intake: low (<33rd percentile), middle (33–66rd percentile) and 
high (>66rd percentile) based on unique individuals included in 
the analysis. Two- sided p- values are reported. Statistical signifi-
cance was determined when the p- value was <0.05. All statis-
tical analyses were performed using SAS V.9.4.
resulTs
 Association of viral exposures with CDA
The highest coverage of stool samples (available in 72.9% of 
the case–control pairs) was at 9 months where after the number 
gradually declined and at 24 months samples were available in 
21.7% of the pairs (figure 2). Among the available stool samples 
at each collection age, the percentage of samples positive for 
any virus fluctuated between 22% and 50% without no obvious 
peaks at any collection age (figure 2A). The frequency of entero-
virus positive samples ranged from 0% to 21% from the age 6 
months onwards (figure 2B).
Between the time of first introduction of gluten at median 6 
months of age and 1 year of age, 63 cases compared with 72 
controls had at least one viral exposure (table 2). Enterovirus 
and adenoviruses were detected in 17 and 56 cases compared 
with 19 and 65 controls, respectively. Reoviral exposures were 
detected in only one case and one control, and rotaviral expo-
sures were detected only in one of the controls. The cumulative 
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Table 2 HLA- adjusted OR of cumulative virus detections in stool up 
to 1 year of age from a matched CDA case and control study
Virus/serotype Or (95% CI) P value
Cases 
positive (n)†
Controls 
positive (n)†
Any virus 0.68 (0.49 to 0.94) 0.02 63 72
HEV* 0.97 (0.56 to 1.70) 0.92 17 19
  HEV A 1.65 (0.56 to 4.84) 0.36 8 6
   CVA 6.69 (0.70 to 63.79) 0.1 8 2
  HEV B 1.64 (0.77 to 3.53) 0.2 12 8
   CVB 1.85 (0.81 to 4.24) 0.15 12 7
   Echovirus 1.92 (0.68 to 5.45) 0.22 9 6
HAdV* 0.69 (0.48 to 0.99) 0.04 56 65
  HAdV A 0.56 (0.13 to 2.36) 0.43 3 3
  HAdV B NA NA 1 3
  HAdV C 0.72 (0.37 to 1.37) 0.31 19 23
  HAdV F 3.62 (0.70 to 18.88) 0.13 10 5
Astrovirus 0.94 (0.42 to 2.11) 0.89 15 18
Norovirus 1.10 (0.48 to 2.52) 0.82 12 11
Reovirus 0.71 (0.03 to 18.69) 0.84 1 1
Rotavirus NA NA 0 1
Total number of pairs with available stool samples is 79.
*Species and serotypes of HEV and HAdV are based on virome capsid mapping 
after Vipie genus taxonomy identification as follows: enterovirus capsid (VP1-4) 
repository includes CVA9, CVB1-6, Echovirus 6, 11, 18, 25 and 30. Adenovirus 
resource includes penton, hexon and fibre regions from prototypes AC_000007, 
X73487, JX423382, NC_010956, NC_001454 and KF303071.
†Number refers to the number of children having at least one viral sequence read 
in the stool.
CDA, coeliac disease autoantibody positivity; CVA, coxsackievirus A; CVB, 
coxsackievirus B; HAdV, human adenovirus; HEV, human enterovirus; NA, not 
applicable.
Table 3 HLA- adjusted OR of cumulative viral detections in stool between 1 and 2 years of age: a matched CDA case and controls study
Virus/serotype Or (95% CI) P value Cases positive (n)† Controls positive (n)† Or (95% CI) excluding pairs with IA first‡
Any virus 1.60 (1.12 to 2.29) 0.01 59 58 1.02 (0.56 to 1.83)
HEV* 2.56 (1.19 to 5.51) 0.02 31 16 1.04 (0.42 to 2.56)
  HEV A 2.10 (0.67 to 6.60) 0.2 13 8 0.65 (0.13 to 3.15)
   CVA 2.53 (0.73 to 8.78) 0.15 7 5 0.64 (0.06 to 6.96)
  HEV B 2.64 (0.84 to 8.36) 0.1 15 7 1.32 (0.32 to 5.41)
   CVB 6.00 (1.27 to 28.46) 0.02 16 6 2.45 (0.45 to 13.3)
   Echovirus 2.27 (0.68 to 7.61) 0.18 11 6 1.86 (0.42 to 8.21)
HAdV* 1.41 (0.99 to 2.02) 0.05 52 55 1.03 (0.59 to 1.77)
  HAdV A 5.11 (0.71 to 36.63) 0.1 9 1 NA
  HAdV B 6.12 (0.55 to 67.70) 0.14 4 1 2.46 (0.21 to 28.7)
  HAdV C 1.74 (0.82 to 3.70) 0.15 19 17 1.31 (0.45 to 3.88)
  HAdV F 1.09 (0.23 to 5.11) 0.91 7 7 2.87 (0.21 to 39.1)
Astrovirus 0.70 (0.29 to 1.68) 0.42 13 18 0.45 (0.10 to 1.99)
Norovirus 1.04 (0.42 to 2.62) 0.93 10 11 0.33 (0.05 to 3.00)
Reovirus NA NA 1 0 NA
Rotavirus NA NA 0 0 NA
Total number of pairs with available stool samples is 72.
*Species and serotypes of HEV and HAdV are based on virome capsid mapping after Vipie genus taxonomy identification as follows: enterovirus capsid (VP1-4) repository 
includes CVA9, CVB1-6, Echovirus 6, 11, 18, 25 and 30. Adenovirus resource includes penton, hexon and fibre regions from prototypes AC_000007, X73487, JX423382, 
NC_010956, NC_001454 and KF303071.
†Number refers to the number of children having at least one viral sequence read in the stool.
‡Excluded pairs were those with CDA cases being positive for IA or T1D prior to CDA (n=31) or controls being IA positive by the CDA cases’ seroconversion (n=11).
CDA, coeliac disease autoantibody positivity; CVA, coxsackievirus A; CVB, coxsackievirus B; HAdV, human adenovirus; HEV, human enterovirus; IA, islet autoimmunity; NA, not 
applicable; T1D, type 1 diabetes.
amount of any viral exposures (OR 0.68, 95% CI 0.49 to 0.94, 
p=0.02), and specifically those by adenoviruses (OR 0.69, 
95% CI 0.48 to 0.99, p=0.04), were inversely associated with 
CDA when adjusting for HLA (table 2). None of the other indi-
vidual viruses were associated with CDA.
Between 1 and 2 years of age, 59 cases compared with 58 
controls had at least one positive stool sample with any of the 
selected viruses (table 3). Adenoviruses were detected in 52 cases 
compared with 55 controls, whereas enteroviruses were detected 
in 31 cases compared with 16 controls. Reovirus sequences were 
detected in one case, but none of the controls, while rotavirus 
sequences were not detected in any subjects. Cumulative number 
of positive stool samples for any virus was associated with an 
increased risk for CDA (OR 1.60, 95% CI 1.12 to 2.29, p=0.01). 
Of the different viruses, enteroviruses conferred the strongest 
positive association with CDA (OR 2.56, 95% CI 1.19 to 5.51, 
p=0.02) (table 3). When excluding the enteroviruses, the associ-
ation of any viruses with the development of CDA was lost (OR 
1.35, 95% CI 0.92 to 1.98, p=0.13). The ORs for the entero-
virus B group were in the same direction when excluding the 42 
pairs where either the case or control developed IA or T1D prior 
to seroconversion of CDA, although the reduced sample size did 
not have enough power to show differences between the groups 
(table 3).
 effects of feeding habits and viral exposures on the risk of 
CDA
The cumulative amount of any viral infections or enteroviruses 
during the period after gluten introduction but while breast-
feeding was still ongoing was not associated with CDA (OR 
1.15, 95% CI 0.72 to 1.82, p=0.56 and OR 0.98, 95% CI 0.43 
to 2.21, p=0.96, respectively). When restricting the analysis to 
the time period after the end of any breastfeeding and to stool 
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Figure 3 Effect of the enteroviral exposures between 1 and 2 years of age and risk of coeliac disease autoimmunity stratified by cumulative gluten 
consumption up to 2 years of age.
Table 4 HLA- adjusted interactions of specific viruses or virus 
serotypes between 1 and 2 years of age with the cumulative amount 
of ingested gluten up to the age of 2 years
Virus/serotype P value
Any virus 0.41
HEV 0.03
  HEV A 0.05
   CVA 0.83
  HEV B 0.04
   CVB 0.1
   Echovirus 0.1
HAdV 0.5
  HAdV A 0.81
  HAdV B 0.44
  HAdV C 0.76
  HAdV F 0.15
Astrovirus 0.37
Norovirus 0.08
Reovirus NA
Rotavirus NA
CVA, coxsackievirus A; CVB, coxsackievirus B; HAdV, human adenovirus; HEV, human 
enterovirus;NA, not applicable.
samples collected between 1 and 2 years of age when the chil-
dren were exposed to gluten, both the cumulative amount of any 
virus sequence reads (OR 1.41, 95% CI 1.00 to 2.00, p=0.05) 
and enterovirus sequence reads (OR 2.47, 95% CI, 1.12 to 5.48, 
p=0.03) were associated with CDA.
There was a significant interaction between enteroviruses 
between 1 and 2 years of age and the cumulative gluten intake by 
2 years of age in the risk of CDA (p=0.03) (table 4). The risk of 
CDA was the highest among enterovirus positive children who 
had the highest cumulative gluten intake by 2 years of age (OR 
8.3 (95% CI 1.8 to 37.1), as compared with those consuming 
middle or low amounts (OR 2.9, 95% CI 1.2 to 7.1 and OR 1.0, 
95% CI 0.4 to 2.8, respectively) figure 3.
DIsCussIOn
This study showed that the cumulative number of stool entero-
viral exposures between 1 and 2 years of age was associated with 
CDA. In addition, an interaction between enteroviral exposures 
and gluten intake was observed. More importantly, the risk of 
CDA was increased in cases reporting higher intake of gluten. 
These results indicate that enteroviral exposure augmented by 
higher gluten intake could act as triggers of coeliac disease in 
genetically at- risk children.
Only few previous studies have reported an association 
between enteroviruses and coeliac disease of which one study 
found an increased number of tTG autoantibody positive subjects 
among individuals with a proven enteroviral infection.25 In addi-
tion, enteroviruses have previously been detected in the small 
bowel mucosa of coeliac disease patients.26 Moreover, entero-
viral infections prior to 1 year of age were not associated with 
increased risk of coeliac disease, while those occurring after the 
age of 1 year increased the risk.12 27 Our findings are consistent 
with both of these previous studies. Additionally, in line with 
the Norwegian study,12 our results also showed that enterovi-
ruses increased the risk of CDA only when restricting the anal-
ysis to the period when breastfeeding had ceased, but not while 
breastfeeding was still ongoing. As breastfeeding does not seem 
to be associated with the development of coeliac disease,28 29 this 
finding might indicate that enteroviral infections modulate CDA 
risk at an age when the child has ceased being breastfed.
This study extends previous investigations by showing an 
interaction between cumulative enteroviral exposures between 
age 1 and 2 with cumulative amount of gluten intake by 2 years 
of age. In addition, enteroviruses were associated with high risk, 
particularly among children reporting higher gluten intake, indi-
cating that the gluten amount could amplify the effect of entero-
viruses in the development of CDA. As comprehensive BLAST 
searches of the enterovirus contigs compiled from the NGS- 
derived enterovirus sequence reads did not reveal hits to gluten 
(data not shown), molecular mimicry likely does not account 
for the additive risk effect. Distinct isolate of reovirus, T1L has 
recently been shown to abrogate oral tolerance to gluten in a 
mechanism involving a type 1 interferon- induced activation of 
gluten- specific inflammatory T cells and inhibition of regulatory 
T cells.15 30 Along with these, the T1L reovirus infection was also 
reported to activate tTG.15 As enteroviruses have been shown to 
induce type 1 interferons,31 it could be speculated that entero-
viruses may promote the development of coeliac disease by a 
mechanism involving an enterovirus- induced type 1 interferon- 
mediated breakage of oral tolerance to gluten coupled with acti-
vation of tTG similar to reovirus. Higher gluten intake will result 
in more gliadin peptides available for tTG- mediated deamida-
tion resulting in augmented activation of the immune system 
ultimately leading chronic gut inflammation.
According to our results, cumulative adenoviral infections 
were associated with reduced risk for CDA after gluten introduc-
tion up to 1 year of age suggesting a putatively protective role. 
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Our finding thus contradicts previous results that have pointed 
to either an inductive role11 32 33 or no role at all.12 34 35 Since 
none of the previous studies focused on the age window before 
1 year of age, our finding of a possible protective effect of adeno-
viral infections warrants further research. However, if additional 
studies confirm the protective effect of adenovirus infections 
prior to 1 year of age, the diverging findings of negative and 
positive associations before and after 1 year of age raises the idea 
of a more generalised effective time- window effect. Contrib-
uting factors might involve the loss of immune protection from 
maternal antibodies as well as changes, also other than breast-
feeding in the feeding habit that occur around 1 year of age.
Previous studies based on vaccination data or determination 
of rotavirus targeted antibodies have suggested that rotaviruses 
could trigger coeliac disease.10 13 14 36 Other studies applying 
animal models or circulating reovirus antibodies indicate a role 
of reoviruses in the disease pathogenesis.15 30 In the present 
study, rotavirus and reovirus sequence reads were detected in 
a minority of the stool samples. In the case of rotavirus, this is 
consistent with previous reports using PCR for virus detection 
in the stool.37 Both rotavirus and reovirus are rapidly cleared 
from the stools after an infection.38 Thus, more frequent stool 
sampling and other methods would therefore be required to 
detect short- lived or transiently occurring stool viruses in this 
study.
A major strength of this study is the design of analysing viral 
exposures from prospectively collected stool samples from birth 
until 2 years of age in cases compared with matched controls. 
Another strength is that our analysis focuses on viral exposures 
detected using capsid protein mappings prior to development of 
CDA, which can delineate disease progression and timing on the 
study outcome. However, the CDA case–control pairs were iden-
tified among either IA or T1D NCC pairs which resulted in high 
percentage of IA positive subjects in our cohort. As enterovirus 
infections are associated with the induction of beta- cell autoim-
munity,39 it is possible that the higher frequency of IA positive 
subjects among the CDA cases may have confounded the results. 
In addition, the variation of sequence coverage and number of 
subject pairs restricted the identification of individual entero-
virus types, which limits the analysis to species level. Another 
potential limitation was not adjusting for having a first- degree 
family member with coeliac disease. This was not carried out 
in order to avoid a selection bias due to more likely antibody 
screening of family members among the CDA cases.
In conclusion, the present study found that a cumulative 
number of stool enteroviral exposures is associated with CDA in 
children at genetic risk for coeliac disease. In addition, the inter-
action of enteroviral exposures and higher gluten intake indicate 
a cumulative effect of these factors in the development of CDA.
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